^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Cereblon modulator

    Related drugs:
    6d
    Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting | N=198 --> 74 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Oct 2024 --> Dec 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    7d
    Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse (clinicaltrials.gov)
    P2, N=65, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Oct 2027 --> Dec 2028 | Trial primary completion date: Jan 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    golcadomide (CC-99282)
    13d
    BELAMI: A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Centre Hospitalier Universitaire de Saint Etienne
    New P2 trial
    |
    Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    14d
    Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Allison Winter
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • pemetrexed • dexamethasone • golcadomide (CC-99282)
    28d
    Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Abdullah Khan | Recruiting --> Active, not recruiting | N=27 --> 12
    Enrollment closed • Enrollment change • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • mezigdomide (CC-92480) • dexamethasone injection
    29d
    Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways. (PubMed, Blood)
    Mezigdomide treatment in exhausted T cells results in decreased expression of exhaustion-related markers, increased proinflammatory cytokine expression, and enhanced target cell killing with Alnuctamab, a B-cell maturation antigen (BCMA) targeting TCE. This study provides crucial mechanistic insights into the roles of IKZF1/IKZF3 in T cell exhaustion, supporting the rationale for combining mezigdomide with TCEs to enhance therapeutic outcomes in MM.
    Journal • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
    |
    alnuctamab (CC-93269) • mezigdomide (CC-92480)
    1m
    A Rollover Study of CC-122 (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Feb 2026 --> Oct 2026 | Trial primary completion date: Feb 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone • avadomide (CC-122)
    1m
    Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, City of Hope Medical Center
    New P1/2 trial
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    1m
    Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies. (PubMed, Blood)
    Finally, we demonstrate the ability of Mezigdomide to enhance survival outcomes from anti-BCMA CAR-T therapy in vivo. Overall, our data show that Mezigdomide treatment improves anti-myeloma T cell therapy efficacy and reduces T cell dysfunction by abrogating Ikaros-mediated upregulation of exhaustion genes.
    Journal • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    mezigdomide (CC-92480)
    1m
    Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer. (PubMed, J Proteome Res)
    Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.
    Journal
    |
    IKZF2 (IKAROS family zinc finger 2)
    |
    pomalidomide • iberdomide (CC-220) • mezigdomide (CC-92480)
    2ms
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=4, Terminated, Celgene | N=156 --> 4 | Active, not recruiting --> Terminated; Business objectives have changed
    Enrollment change • Trial termination
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    2ms
    Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, University of Pittsburgh | N=30 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Opdivo (nivolumab) • golcadomide (CC-99282)